For many years, the most effective wound care allografts came in mostly large sizes with few options in terms of sheet dimensions. This resulted in unnecessary costs and a large volume of waste, because once these products are freed from their sanitary packaging they must be used quickly in a sterile environment, and only on one patient at a time.
MiMedx has not only created a human amnion/chorion membrane (dHACM) allograft that is as effective or better at treating wounds than Apligraf or Dermagraft, but they also offer their EpiFix product in a multitude of dimensions, which significantly reduces waste and expenses for physicians treating patients with ailments such as diabetic foot wounds and venous leg wounds.
Charles M. Zelen, DPM, FACFAS
Contracted Research: MiMedx